PHARMACOECONOMIC BENEFITS OF CYTOMEGALOVIRUS INFECTION PROPHYLACTIC STRATEGY FOR RENAL TRANSPLANT RECIPIENTS
CMV infection is a major problem in kidney transplantation patients. Valcyte, Cimevene are the first line thera- py of CMV infection. This pharmacoeconomic analysis shown economic benefits of Valcyte prophylaxis tactic compare preemptive strategy.
Saved in:
| Main Authors: | V. V. Ryazhenov, S. G. Gorokhova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
2011-06-01
|
| Series: | Вестник трансплантологии и искусственных органов |
| Subjects: | |
| Online Access: | https://journal.transpl.ru/vtio/article/view/411 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis
by: A. V. Rudakova, et al.
Published: (2021-07-01) -
The Seropositivity Rate of Human Cytomegalovirus [Hcmv] Among Hepatitis B Virus [Hbv] Patients, Hepatitis C Virus [Hcv] Patients, and Blood Donors in Diyala Province
by: Dhaffir Hashim Steer, et al.
Published: (2024-01-01) -
Effector-Memory γδ T Lymphocytes Predict CMV Disease After the Withdrawal of Prophylaxis in Kidney Transplant Recipients
by: Yoann Abadie, et al.
Published: (2025-07-01) -
Reactivation of cytomegalovirus, human herpes virus, and Epstein-Barr virus infections after hemapoietic stem cell transplantation in children
by: T. V. Antonova, et al.
Published: (2024-01-01) -
An impact of CMV and HHV-6 reactivation on the course of early period after hematopoietic stem cell transplantation in patients with hematologic malignancies
by: T. V. Antonova, et al.
Published: (2023-01-01)